Akshara Raghavendra, M.D., M.S.

Peer-Reviewed Articles

1. Singareeka Raghavendra, A, Kettner, NM, Kwiatkowski, DN, Damodaran, S, Wang, Y, Ramirez, DL, Gombos, DS, Hunt, KK, Shen, Y, Keyomarsi, K, Tripathy, D. Phase I trial of hydroxychloroquine to enhance palbociclib and letrozole efficacy in ER+/HER2− breast cancer. npj Breast Cancer 11(1), 2025. e-Pub 2025. PMID: 39865083.
2. Luo, L, Yang, P, Mastoraki, S, Rao, X, Wang, Y, Kettner, NM, Singareeka Raghavendra, A, Tripathy, D, Damodaran, S, Hunt, KK, Wang, J, Li, Z, Keyomarsi, K. Single-cell RNA sequencing identifies molecular biomarkers predicting late progression to CDK4/6 inhibition in patients with HR+/HER2- metastatic breast cancer. Molecular cancer 24(1), 2025. e-Pub 2025. PMID: 39955556.
3. Strahan A, Jin Q, Raghavendra AS, Zakon DB, Grimm M, Hughes ME, Cherian M, Vincuilla J, Parker T, Tarantino P, Johnson KCC, Mittendorf EA, King TA, Valero V, Tripathy D, Tolaney SM, Tayob N, Lin NU, Stover DG, Barcenas CH, Garrido-Castro AC. Adjuvant capecitabine in patients with triple-negative breast cancer after neoadjuvant chemotherapy. ESMO Open 10(9):105568, 2025. e-Pub 2025. PMID: 40882247.
4. Kettner NM, Bui TN, Navarro-Yepes J, Ghotbaldini S, Quintela B, Luo CK, Lam N, Rao X, Raghavendra AS, Wang Y, Azizian N, Kris Eckols T, Kasembeli MM, Evans K, Yi M, Wingate H, Wang J, Sahin AA, Meric-Bernstam F, Hunt KK, Damodaran S, Tweardy DJ, Tripathy D, Keyomarsi K. IL-6 predicts CDK4/6 inhibitor resistance, identifying STAT3 as a target in HR + /HER2-negative metastatic breast cancer. NPJ Precis Oncol 9(1):260, 2025. e-Pub 2025. PMID: 40715551.
5. Raghavendra AS, Bassett R Jr, Damodaran S, Barcenas CH, Mouabbi JA, Layman R, Tripathy D. Clinical Characteristics and Survival Outcomes of Metastatic Invasive Lobular and Ductal Carcinoma. JAMA Netw Open 8(4):e251888, 2025. e-Pub 2025. PMID: 40293750.
6. Raghavendra AS, Zakon DB, Jin Q, Strahan A, Grimm M, Hughes ME, Cherian M, Vincuilla J, Parker T, Tarantino P, Mittendorf EA, King TA, Valero V, Tripathy D, Tolaney SM, Tayob N, Lin NU, Stover DG, Barcenas CH, Garrido-Castro AC. Clinical outcomes of early-stage triple-negative breast cancer after neoadjuvant chemotherapy according to HER2-low status☆. ESMO Open 9(11):103973, 2024. e-Pub 2024. PMID: 39500139.
7. Jayan A, Sukumar JS, Fangman B, Patel T, Raghavendra AS, Liu D, Pasyar S, Rauch R, Basen-Engquist K, Tripathy D, Wang Y, Khan SS, Barcenas CH. Real-World Immune-Related Adverse Events in Patients With Early Triple-Negative Breast Cancer Who Received Pembrolizumab. JCO Oncol Pract 21(9):OP2400371, 2024. e-Pub 2024. PMID: 39388649.
8. Singareeka Raghavendra, A, Liu, D, Shen, Y, Barcenas, CH, Ueno, NT, Giordano, SH, Tripathy, D, Karuturi, MS. Outcomes of older adults with early-stage triple-negative breast cancer (TNBC) receiving chemotherapy. Breast Cancer Research and Treatment 207(1):81-90, 2024. e-Pub 2024. PMID: 38916821.
9. Raghavendra AS, Jennings K, Guerra G, Tripathy D, Karuturi MS. Patient-reported convenience and effectiveness of telehealth for breast cancer management. Oncologist 29(11):e1470-e1479, 2024. e-Pub 2024. PMID: 39017637.
10. Mouabbi, JA, Qaio, W, Shen, Y, Singareeka Raghavendra, A, Tripathy, D, Layman, RM. Efficacy of Single-Agent Chemotherapy in Endocrine Therapy-Refractory Metastatic Invasive Lobular Carcinoma. Oncologist 29(3):213-218, 2024. e-Pub 2024. PMID: 38070191.
11. Garber, HR, Basu, S, Jindal, S, He, Z, Chu, K, Singareeka Raghavendra, A, Yam, C, Santiago, L, Adrada, BE, Sharma, P, Mittendorf, EA, Litton, J. Durvalumab and tremelimumab before surgery in patients with hormone receptor positive, HER2-negative stage II–III breast cancer. Oncotarget 15:238-247, 2024. e-Pub 2024. PMID: 38502947.
12. Iwase, T, Parikh, A, Wenli, D, Shen, Y, Adams, DL, Tang, CM, Cohen, E, Reuben, JM, Shrimanker, TV, Chainitikun, S, Kida, K, Singareeka Raghavendra, A, Sapon, ME, Sahin, O, James, A, Sridhar, N, Klopp, AH, Tripathy, D, Ueno, NT. Circulating cancer-associated macrophage-like cells and macrophage-related cytokines in obese patients with advanced breast cancer who undergo neoadjuvant chemotherapy. Journal of Cancer 15(18):5855-5862, 2024. e-Pub 2024. PMID: 39440056.
13. Iwase T, Parikh A, Wenli D, Shen Y, Adams DL, Tang CM, Cohen EN, Reuben JM, Shrimanker TV, Chainitikun S, Kida K, Raghavendra AS, Sapon ME, Sahin O, James A, Sridhar N, Klopp AH, Tripathy D, Ueno NT. Circulating cancer-associated macrophage-like cells and macrophage-related cytokines in obese patients with advanced breast cancer who undergo neoadjuvant chemotherapy. J Cancer 15(18):5855-5862, 2024. e-Pub 2024. PMID: 39440056.
14. Liu, S, Xie, SM, Liu, W, Gagea Iurascu, M, Hanker, AB, Nguyen, N, Singareeka Raghavendra, A, Yang-Kolodji, G, Chu, F, Neelapu, SS, Marchese, A, Hanash, S, Zimmermann, J, Arteaga, CL, Tripathy, D. Targeting CXCR4 abrogates resistance to trastuzumab by blocking cell cycle progression and synergizes with docetaxel in breast cancer treatment. Breast Cancer Research 25(1), 2023. e-Pub 2023. PMID: 37280713.
15. Jayan, A, Singareeka Raghavendra, A, Bassett Jr, R, Barcenas, CH. Bone-Targeted Therapy Regimen and Skeletal-Related Events in Patients Surviving Longer Than 2 Years With Metastatic Breast Cancer and Bone Metastasis. Clinical breast cancer 23(8):e515-e522, 2023. e-Pub 2023. PMID: 37735019.
16. Navarro-Yepes, J, Kettner, NM, Rao, X, Bishop, CS, Bui, T, Wingate, H, Singareeka Raghavendra, A, Wang, Y, Wang, J, Sahin, AA, Meric-Bernstam, F, Hunt, KK, Damodaran, S, Tripathy, D, Keyomarsi, K. Abemaciclib Is Effective in Palbociclib-Resistant Hormone Receptor–Positive Metastatic Breast Cancers. Cancer Research 83(19):3264-3283, 2023. e-Pub 2023. PMID: 37384539.
17. Mouabbi, JA, Singareeka Raghavendra, A, Bassett Jr, R, Christgen, M, Middleton, LP, Teshome, M, Nasrazadani, A, Hortobagyi, GN, Hassan, A, Tripathy, D, Layman, RM. Absence of lobular carcinoma in situ is a poor prognostic marker in invasive lobular carcinoma. European Journal of Cancer 191, 2023. e-Pub 2023. PMID: 37573674.
18. mouabbi, Raghavendra A, Bassett Jr R, Hassan A, Tripathy D, Layman R. Survival outcomes in HR+ HER2-low versus HR+ HER2 0 metastatic breast cancer treated with targeted therapies plus endocrine therapy. JAMA Network Open, 2023. PMID: 37166793.
19. Mouabbi, JA, Singareeka Raghavendra, A, Bassett Jr, R, Hassan, A, Tripathy, D, Layman, RM. Survival Outcomes in Patients with Hormone Receptor-Positive Metastatic Breast Cancer with Low or No ERBB2 Expression Treated with Targeted Therapies Plus Endocrine Therapy. JAMA Network Open 6(5):E2313017, 2023. e-Pub 2023. PMID: 37166793.
20. Liu S, Xie SM, Liu W, Gagea M, Hanker AB, Nguyen N, Raghavendra AS, Yang-Kolodji G, Chu F, Neelapu SS, Hanash S, Zimmermann J, Arteaga CL, Tripathy D. Targeting CXCR4 abrogates resistance to trastuzumab by blocking cell cycle progression and synergizes with docetaxel in breast cancer treatment. Res Sq, 2023. e-Pub 2023. PMID: 36824840.
21. Kabraji S, Ni J, Sammons S, Li T, Van Swearingen AED, Wang Y, Pereslete A, Hsu L, DiPiro PJ, Lascola C, Moore H, Hughes M, Raghavendra AS, Gule-Monroe M, Murthy RK, Winer EP, Anders CK, Zhao JJ, Lin NU. Preclinical and clinical efficacy of trastuzumab deruxtecan in breast cancer brain metastases. Clin Cancer Res 29(1):174-182, 2023. e-Pub 2022. PMID: 36074155.
22. Mouabbi, JA, Singareeka Raghavendra, A, Bassett Jr, R, Hassan, A, Tripathy, D, Layman, RM. Histology-based survival outcomes in hormone receptor-positive metastatic breast cancer treated with targeted therapies. npj Breast Cancer 8(1), 2022. e-Pub 2022. PMID: 36539444.
23. Zuo Q, Mogol AN, Liu YJ, Santaliz Casiano A, Chien C, Drnevich J, Imir OB, Kulkoyluoglu-Cotul E, Park NH, Shapiro DJ, Park BH, Ziegler Y, Katzenellenbogen BS, Aranda E, O'Neill JD, Raghavendra AS, Tripathy D, Madak Erdogan Z. Targeting Metabolic Adaptations in the Breast Cancer-Liver Metastatic Niche Using Dietary Approaches to Improve Endocrine Therapy Efficacy. Mol Cancer Res 20(6):923-937, 2022. e-Pub 2022. PMID: 35259269.
24. Ha MJ, Singareeka Raghavendra A, Kettner NM, Qiao W, Damodaran S, Layman RM, Hunt KK, Shen Y, Tripathy D, Keyomarsi K. Palbociclib plus endocrine therapy significantly enhances overall survival of HR+/HER2- metastatic breast cancer patients compared to endocrine therapy alone in the second-line setting: A large institutional study. Int J Cancer 150(12):2025-2037, 2022. e-Pub 2022. PMID: 35133007.
25. Kaler A, McClosky V, Raghavendra AS, Tripathy D. Oral Oncolytics: Using Remote Technology to Improve Access, Operational Efficiency, and Satisfaction. Clin J Oncol Nurs 26(3):308-312, 2022. e-Pub 2022. PMID: 35604739.
26. Garber HR, Raghavendra AS, Lehner M, Qiao W, Gutierrez-Barrera AM, Tripathy D, Arun B, Ibrahim NK. Incidence and impact of brain metastasis in patients with hereditary BRCA1 or BRCA2 mutated invasive breast cancer. NPJ Breast Cancer 8(1):46, 2022. e-Pub 2022. PMID: 35393462.
27. Singareeka Raghavendra A, Kypriotakis G, Karam-Hage M, Kim S, Jizzini M, Seoudy KS, Robinson JD, Barcenas CH, Cinciripini PM, Tripathy D, Ibrahim NK. The Impact of Treatment for Smoking on Breast Cancer Patients' Survival. Cancers (Basel) 14(6), 2022. e-Pub 2022. PMID: 35326615.
28. Fujii T, Masuda H, Cheng YC, Yang F, Sahin AA, Naoi Y, Matsunaga Y, Raghavendra A, Sinha AK, Fernandez JRE, James A, Yamagishi K, Matsushima T, Schuetz R, Tripathy D, Tada S, Jackson RS, Noguchi S, Nakamura S, Acoba JD, Ueno NT. A 95-gene signature stratifies recurrence risk of invasive disease in ER-positive, HER2-negative, node-negative breast cancer with intermediate 21-gene signature recurrence scores. Breast Cancer Res Treat 189(2):455-461, 2021. e-Pub 2021. PMID: 34131830.
29. Barcenas CH, Song J, Murthy RK, Raghavendra AS, Li Y, Hsu L, Carlson RW, Tripathy D, Hortobagyi GN. Prognostic Model for De Novo and Recurrent Metastatic Breast Cancer. JCO Clin Cancer Inform 5:789-804, 2021. e-Pub 2021. PMID: 34351787.
30. Singareeka Raghavendra A, Alameddine HF, Andersen CR, Selber JC, Brewster AM, Barcenas CH, Caudle AS, Arun BK, Tripathy D, Ibrahim NK. Influencers of the Decision to Undergo Contralateral Prophylactic Mastectomy among Women with Unilateral Breast Cancer. Cancers (Basel) 13(9), 2021. e-Pub 2021. PMID: 33922702.
31. Gao C, Wang F, Suki D, Strom E, Li J, Sawaya R, Hsu L, Raghavendra A, Tripathy D, Ibrahim NK. Effects of systemic therapy and local therapy on outcomes of 873 breast cancer patients with metastatic breast cancer to brain: MD Anderson Cancer Center experience. Int J Cancer 148(4):961-970, 2021. e-Pub 2021. PMID: 32748402.
32. Wecsler J, Jeong YJ, Raghavendra AS, Mack WJ, Tripathy D, Yamashita MW, Sheth PA, Hovanessian Larsen L, Russell CA, MacDonald H, Sener SF, Lang JE. Factors associated with MRI detection of occult lesions in newly diagnosed breast cancers. J Surg Oncol 121(4):589-598, 2020. e-Pub 2020. PMID: 31984517.
33. Murthy RK, Song J, Raghavendra AS, Li Y, Hsu L, Hess KR, Barcenas CH, Valero V, Carlson RW, Tripathy D, Hortobagyi GN. Incorporation of clinical and biological factors improves prognostication and reflects contemporary clinical practice. NPJ Breast Cancer 6:11, 2020. e-Pub 2020. PMID: 32219153.
34. Kettner NM, Vijayaraghavan S, Durak MG, Bui T, Kohansal M, Ha MJ, Liu B, Rao X, Wang J, Yi M, Carey JPW, Chen X, Eckols TK, Raghavendra AS, Ibrahim NK, Karuturi MS, Watowich SS, Sahin A, Tweardy DJ, Hunt KK, Tripathy D, Keyomarsi K. Combined Inhibition of STAT3 and DNA Repair in Palbociclib-Resistant ER-Positive Breast Cancer. Clin Cancer Res 25(13):3996-4013, 2019. e-Pub 2019. PMID: 30867218.
35. Baez-Vallecillo L, Raghavendra AS, Hess KR, Barcenas CH, Moulder SL, Tripathy D, Valero V, Murthy RK. Lapatinib activity in metastatic human epidermal growth factor receptor 2-positive breast cancers that received prior therapy with trastuzumab, pertuzumab, and/or ado-trastuzumab emtansine (T-DM1). Breast Cancer Res Treat 176(1):227-234, 2019. e-Pub 2019. PMID: 30977027.
36. Yam C, Esteva FJ, Patel MM, Raghavendra AS, Ueno NT, Moulder SL, Hess KR, Shroff GS, Hodge S, Koenig KH, Chavez Mac Gregor M, Griner RL, Yeung SJ, Hortobagyi GN, Valero V. Efficacy and safety of the combination of metformin, everolimus and exemestane in overweight and obese postmenopausal patients with metastatic, hormone receptor-positive, HER2-negative breast cancer: a phase II study. Invest New Drugs 37(2):345-351, 2019. e-Pub 2019. PMID: 30610588.
37. Raghavendra A, Wecsler J, Ji L, Sheth P, Ricker C, Church T, Sposto R, Lang J, Sener S, Larsen L, Tripathy D. Clinical findings and outcomes of MRI staging of breast cancer in a diverse population. Breast Cancer Res Treat 174(2):315-324, 2019. e-Pub 2019. PMID: 30542816.
38. Wong Y, Raghavendra AS, Hatzis C, Irizarry JP, Vega T, Horowitz N, Barcenas CH, Chavez-MacGregor M, Valero V, Tripathy D, Pusztai L, Murthy RK. Long-Term Survival of De Novo Stage IV Human Epidermal Growth Receptor 2 (HER2) Positive Breast Cancers Treated with HER2-Targeted Therapy. Oncologist 24(3):313-318, 2019. e-Pub 2019. PMID: 30139836.
39. Caswell-Jin JL, McNamara K, Reiter JG, Sun R, Hu Z, Ma Z, Ding J, Suarez CJ, Tilk S, Raghavendra A, Forte V, Chin SF, Bardwell H, Provenzano E, Caldas C, Lang J, West R, Tripathy D, Press MF, Curtis C. Clonal replacement and heterogeneity in breast tumors treated with neoadjuvant HER2-targeted therapy. Nat Commun 10(1):657, 2019. e-Pub 2019. PMID: 30737380.
40. Murthy RK, Raghavendra AS, Hess KR, Fujii T, Lim B, Barcenas CH, Zhang H, Chavez-Mac-Gregor M, Mittendorf EA, Litton JK, Giordano SH, Thompson AM, Valero V, Moulder SL, Tripathy D, Ueno NT. Neoadjuvant Pertuzumab-containing Regimens Improve Pathologic Complete Response Rates in Stage II to III HER-2/neu-positive Breast Cancer: A Retrospective, Single Institution Experience. Clin Breast Cancer 18(6):e1283-e1288, 2018. e-Pub 2018. PMID: 30077429.
41. Gage MM, Mylander WC, Rosman M, Fujii T, Le Du F, Raghavendra A, Sinha AK, Espinosa Fernandez JR, James A, Ueno NT, Tafra L, Jackson RS. Combined pathologic-genomic algorithm for early-stage breast cancer improves cost-effective use of the 21-gene recurrence score assay. Ann Oncol 29(5):1280-1285, 2018. e-Pub 2018. PMID: 29788166.
42. Barcenas CH, Shafaee MN, Sinha AK, Raghavendra A, Saigal B, Murthy RK, Woodson AH, Arun B. Genetic Counseling Referral Rates in Long-Term Survivors of Triple-Negative Breast Cancer. J Natl Compr Canc Netw 16(5):518-524, 2018. e-Pub 2018. PMID: 29752326.
43. Gage MM, Mylander WC, Rosman M, Fujii T, Le Du F, Raghavendra A, Sinha AK, Fernandez JE, James A, Ueno NT, Tafra L. Combined pathologic‐genomic algorithm for early-stage breast cancer improves cost-effective use of the 21-gene recurrence score assay. Annals of Oncology 29(5), 2018. e-Pub 2018.
44. Barcenas CH, Shafaee MN, Sinha AK, Raghavendra A, Saigal B, Murthy RK, Woodson AH, Arun B. Genetic counseling referral rates in long-term survivors of triple-negative breast cancer. Journal of the National Comprehensive Cancer Network 16(5), 2018. e-Pub 2018.
45. Raghavendra A, Sinha AK, Valle-Goffin J, Shen Y, Tripathy D, Barcenas CH. Determinants of Weight Gain During Adjuvant Endocrine Therapy and Association of Such Weight Gain With Recurrence in Long-term Breast Cancer Survivors. Clin Breast Cancer 18(1):e7-e13, 2018. e-Pub 2018. PMID: 29239836.
46. Pan E, Tung L, Ragab O, Morocco E, Wecsler J, Sposto R, Raghavendra A, Chung E, Lang JE. Inflammatory Breast Cancer Outcomes in a Contemporary Series. Anticancer Res 37(9):5057-5063, 2017. e-Pub 2017. PMID: 28870934.
47. Barcenas CH, Raghavendra A, Sinha AK, Syed MP, Hsu L, Patangan MG, Chavez-MacGregor M, Shen Y, Hortobagyi GH, Valero V, Giordano SH, Ueno NT, Tripathy D. Outcomes in patients with early-stage breast cancer who underwent a 21-gene expression assay. Cancer 123(13):2422-2431, 2017. e-Pub 2017. PMID: 28199747.
48. Vijayaraghavan S, Karakas C, Doostan I, Chen X, Bui T, Yi M, Raghavendra AS, Zhao Y, Bashour SI, Ibrahim NK, Karuturi M, Wang J, Winkler JD, Amaravadi RK, Hunt KK, Tripathy D, Keyomarsi K. CDK4/6 and autophagy inhibitors synergistically induce senescence in Rb positive cytoplasmic cyclin E negative cancers. Nat Commun 8:15916, 2017. e-Pub 2017. PMID: 28653662.
49. Raghavendra A, Sinha AK, Le-Petross HT, Garg N, Hsu L, Patangan M, Bevers TB, Shen Y, Banu A, Tripathy D, Bedrosian I, Barcenas CH. Mammographic breast density is associated with the development of contralateral breast cancer. Cancer 123(11):1935-1940, 2017. e-Pub 2017. PMID: 28135395.
50. Fujii T, Kogawa T, Wu J, Sahin AA, Liu DD, Chavez-MacGregor M, Giordano SH, Raghavendra A, Murthy RK, Tripathy D, Shen Y, Yamal JM, Ueno NT. Nomogram to predict pathologic complete response in HER2-positive breast cancer treated with neoadjuvant systemic therapy. Br J Cancer 116(4):509-514, 2017. e-Pub 2017. PMID: 28081544.
51. Dzimitrowicz H, Berger M, Vargo C, Hood A, Abdelghany O, Raghavendra AS, Tripathy D, Valero V, Hatzis C, Pusztai L, Murthy R. T-DM1 Activity in Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancers That Received Prior Therapy With Trastuzumab and Pertuzumab. J Clin Oncol 34(29):3511-3517, 2016. e-Pub 2016. PMID: 27298406.

Invited Articles

1. Raghavendra AS, Tripathy D. How Does MR Imaging Help Care for the Breast Cancer Patient? Perspective of a Medical Oncologist. Magn Reson Imaging Clin N Am 26(2):289-293, 2018. e-Pub 2018. PMID: 29622134.

Review Articles

1. Raghavendra AS, Ibrahim NK. Breast Cancer Brain Metastasis: A Comprehensive Review. JCO Oncol Pract 20(10):1348-1359, 2024. e-Pub 2024. PMID: 38748968.
2. Jayan, A, Sukumar, J, Fangman, B, Patel, TA, Singareeka Raghavendra, A, Liu, D, Rauch, RA, Basen-Engquist, KM, Tripathy, D, Barcenas, CH. Real-world immune-related adverse events in patients with early triple negative breast cancer who received pembrolizumab. Journal of Clinical Oncology 42:1099, 2024. e-Pub 2024.

Other Articles

1. Caswell-Jin JL, McNamara K, Reiter JG, Sun R, Hu Z, Ma Z, Ding J, Suarez CJ, Tilk S, Raghavendra A, Forte V, Chin SF, Bardwell H, Provenzano E, Caldas C, Lang J, West R, Tripathy D, Press MF, Curtis C Publisher Correction: Clonal replacement and heterogeneity in breast tumors treated with neoadjuvant HER2-targeted therapy. Nat Commun 10(1):2433, 2019. PMID: 31147552.

Abstracts

1. Kaler A, Raghavendra AS, Kirklin GT, Cunningham D, Manzullo E, Tripathy D, Razouki Z. Linking Internal Medicine Care to Metastatic Breast Cancer Patients for Success: LIMBS. Cancer Research 83(5 Supplement), 2023. e-Pub 2023.
2. Chien C, Madak-Erdogan Z, Goel M, Gangidi S, Tripathy D, Raghavendra AS. Efficacy of fulvestrant-based therapies in treating HR-positive, HER2-negative breast cancer with liver metastasis. Cancer Research 83(5 Supplement), 2023. e-Pub 2023.
3. Mouabbi J, Raghavendra AS, Christgen M, Hassan A, Hortobagyi GN, Tripathy D, Layman RM. Absence of Lobular Carcinoma In Situ, a Poor Prognostic Marker in Invasive Lobular Carcinoma. Cancer Research 83(5 Supplement), 2023. e-Pub 2023.
4. Raghavendra AS, Liu D, Mouabbi J, Tripathy D. Prevalence of HER2-low among Metastatic Breast Cancer Patients and Their Outcomes Compared to HER2 IHC 0. Cancer Research 83(5 Supplement), 2023. e-Pub 2023.
5. Mouabbi J, Raghavendra AS, Bassett R, Hassan A, Tripathy D, Layman RM. Histology-based survival outcomes in HR+/HER2-metastatic breast cancer treated with targeted therapies plus endocrine therapy based on HER2 expression. Cancer Research 83(5 Supplement), 2023. e-Pub 2023.
6. Raghavendra AS, Bassett R, Mouabbi J, Layman RM, Tripathy D. Biology and clinical course of lobular cancer in breast cancer. Cancer Research 83(5 Supplement), 2023. e-Pub 2023.
7. Mogol A, Chien C, Zuo Q, Raghavendra AS, Tripathy D, Landesman Y, Madak-Erdogan Z. ODP647 Nuclear ERα and NAMPT Crosstalk in Metastatic Breast Tumors. JES 6(1 Suppl):A879, 2022. e-Pub 2022.
8. Chien C, Raghavendra AS, Tripathy D, and Madak-Erdogan Z. ODP563 Breast Cancer With Liver Metastasis Responds Poorly to Fulvestrant-Based Combination Therapy and Chemotherapy. JES 6(1 Suppl):A877-8, 2022. e-Pub 2022.
9. Jayan A, Raghavendra AS, Bassett RL, Barcenas, CH. The effects of bone targeted therapy in patients with greater than two years survival with metastatic breast cancer and bone metastasis. J Clin Oncol 40(16 Suppl), 2022. e-Pub 2022.
10. Mastoraki S, Lin J, Rao X, Liu SR, Batra H, Raso MG, Parra ER, Raghavendra AS, Rasaputra KS, Yi M, Wang J, Sahin A, Tripathy D, Hunt KK, Navin NE, Keyomarsi K. Single-cell transcriptomic analysis of HR+/HER2- breast cancer identifies gene signatures that predict outcomes of luminal A and B subtypes [abstract]. Cancer Res 82(12 Suppl), 2022. e-Pub 2022.
11. Navarro-Yepes J, Kettner NM, Bui T, Raghavendra AS, Rao X, Wang J, Sahin A, Damodaran S, Tripathy D, Hunt KK, Keyamarsi K. Mechanisms of acquired resistance to palbociclib reveals pathways of response to abemaciclib [abstract]. Cancer Res 82(12 Suppl), 2022. e-Pub 2022.
12. Kettner NM, Bui TN, Navarro-Yepes J, Eckols TK, Raghavendra AS, Tweardy DJ, Hunt KK, Tripathy D, Keyomarsi K. Circulating IL-6, an early biomarker in HR-positive, HER2-negative metastatic breast cancer patients progressing on CDK4/6 inhibitors [abstract]. Cancer Res 82(12 Suppl), 2022. e-Pub 2022.
13. Mogol AN, Chien C, Zuo Q, Raghavendra AS, Tripathy D, Landesman Y, Erdogan ZM. ERα and NAMPT crosstalk at enhancers drives Fulvestrant resistance in metastatic breast tumors [abstract]. Cancer Res 82(12 Suppl), 2022. e-Pub 2022.
14. Mouabbi JA, Raghavendra AS, Bassett RL, Hassan AA, Tripathy D, Layman RM. Survival outcomes in metastatic HR-positive, HER2-negative invasive ductal carcinoma compared to invasive lobular carcinoma and mixed ductal/lobular treated with endocrine therapy in combination with CDK4/6 inhibitors, mTOR inhibitor, or PI3K inhibitor 40(16 Supp), 2022. e-Pub 2022.
15. Garber HR, Basu S, Jindal S, Raghavendra AS, Santiago L, Adrada BE, Sharma P, Allison JP, Litton J. Durvalumab and tremelimumab before surgery in patients with hormone receptor positive, HER2 negative stage II-III breast cancer [abstract]. Cancer Res 82(4 Suppl), 2022. e-Pub 2022.
16. Kabraji S, Ni J, Sammons S, Van Swearingen AED, Wang Y, Pereslete AM, Hsu L, Lascola C, Moore H, Hughes M, Raghavendra AS, Gule-Monroe M, Murthy RK, Winer EP, Anders CK, Zhao JJ, Lin NU. Preclinical and clinical efficacy of trastuzumab deruxtecan in breast cancer brain metastases (BCBM) [abstract]. Cancer Res 82(4 Suppl), 2022. e-Pub 2022.
17. Murthy RK, O'Brien B, Berry DA, Raghavendra AS, Monroe MG, Johnson J, White J, Childress J, Sanford J, Schwartz-Gomez J, Melisko M, Morikawa A, Ferguson S, de Groot JF, Krop I, Valero V, Rimawi M, Wolff A, Tripathy D, Lin NU, Stringer-Reasor E. Safety and efficacy of a tucatinib-trastuzumab-capecitabine regimen for treatment of leptomeningeal metastasis (LM) in HER2-positive breast cancer: Results from TBCRC049, a phase 2 non-randomized study [abstract]. Cancer Res 82(4 Suppl), 2022. e-Pub 2022.
18. Raghavendra AS, Ha MJ, Kettner NM, Damodaran S, Layman R, Hunt KK, Shen Y, Tripathy D, Keyomarsi K. Palbociclib plus endocrine therapy significantly enhances overall survival of HR+/HER2- metastatic breast cancer patients compared to endocrine therapy alone - A large institutional study [abstract]. Cancer Res 82(4 Suppl), 2022. e-Pub 2022.
19. Zuo Q, Mogol AN, Liu YJ, Casiano AS, Chien C, Drnevich J, Imir OB, Kulkoyluoglu-Cotul E, Park NH, Shapiro DJ, Park BH, Ziegler Y, Katzenellenbogen BS, Aranda E, O’Neill JD, Raghavendra AS, Tripathy D, Erdogan ZM. Targeting metabolic adaptations in the breast cancer–liver metastatic niche using dietary approaches to improve endocrine therapy efficacy [abstract]. bioRxiv, 2021. e-Pub 2021.
20. Wang Y, An R, Wang F, Raghavendra AS, Gao C, Kim YSB, Briere TM, Amaya D, Li J. Survival and disease control after upfront stereotactic radiosurgery for brain metastases from breast cancer. J Clin Oncol 39(15), 2021. e-Pub 2021.
21. An R, Wang Y, Wang F, Raghavendra AS, Gao C, Amaya D, Ibrahim NK, Li J. Upfront stereotactic radiosurgery for brain metastases from triple-negative breast cancer. J Clin Oncol 39(15 Suppl), 2021. e-Pub 2021.
22. Raghavendra AS, Gao C, Wang F, Wang Y, An R, Suki D, Heimberger A, Tripathy D, Li J, Ibrahim N. Stereotactic radiosurgery (SRS) for brain metastasis (BM) in hormone receptor positive (HR+) HER2 negative breast cancer (BC). J Clin Oncol 39(15 Suppl), 2021. e-Pub 2021.
23. Raghavendra AS, Kwiatkowski D, Damodaran S, Kettner NM, Ramirez DL, Gombos DS, Hunt K, Shen Y, Keyomarsi K, Tripathy D. Phase I safety and efficacy study of autophagy inhibition with hydroxychloroquine to augment the antiproliferative and biological effects of preoperative palbociclib plus letrozole for estrogen receptor-positive, HER2-negative metastatic breast cancer (MBC). J Clin Oncol 39(15 Suppl), 2021. e-Pub 2021.
24. An R, Wang Y, Wang F, Gao C, Raghavendra AS, Amaya D, Ibrahim NK, Li J. Survival outcomes and prognosis for patients with triple negative breast cancer who received stereotactic radiosurgery for brain metastases [abstract]. Cancer Res 81(4 Suppl), 2021. e-Pub 2021.
25. Iwase T, Parikh A, Sahin O, Raghavendra AS, Sapon ME, James A, Shrimanker TV, Chainitikun S, Kida K, Adams DL, Tang CM, Medrano AYD, Klopp AH, Ueno NT. Prospective study of circulating cancer-associated macrophage-like cells (CAMLs) in obese patients with advanced breast cancer [abstract]. Cancer Res 81(4 Suppl), 2021. e-Pub 2021.
26. Alameddine H, Raghavendra AS, Andersen C, Selber J, Brewster A, Barcenas C, Caudle A, Arun B, Ibrahim NK. Decision making process and contralateral prophylactic mastectomy [abstract]. Cancer Res 81(4 Suppl), 2021. e-Pub 2021.
27. An R, Wang Y, Gao C, Raghavendra AS, Amaya D, Ibrahim N, Li J. Survival outcomes and prognosis in patients with triple-negative breast cancer and brain metastases. Radiotherapy and Oncology, 2020. e-Pub 2020.
28. Wang Y, An R, Gao C, Raghavendra AS, Amaya D, Ibrahim N, Li J. Survival outcomes after upfront stereotactic radiosurgery for brain metastases from breast cancer. Radiotherapy and Oncology,. Radiotherapy and Oncology, 2020. e-Pub 2020.
29. Garber H, Lehner M, Raghavendra AS, Gutierrez-Barrera AM, Tripathy D, Litton JK, Arun B, Ibrahim NK. The incidence and impact of brain metastasis in patients with hereditary BRCA1/2 mutated invasive breast cancer in a prospectively followed cohort. J Clin Oncol 38(15), 2020. e-Pub 2020.
30. DuF L, Takeo F, Park M, Hess KR, Liu D, Jackson R, Mylander C, Rosman M, Raghavendra A, Tafra L, Ueno NT. Prediction of the 21-gene recurrence score by a non-genomic approach in stage I estrogen receptor-positive, HER2-negative breast cancer. Ann Oncol 31(2 Suppl):S19-20, 2020. e-Pub 2020.
31. Oke O, Niu J, Raghavendra A, Chavez-McGregor M, Zhao H, Tripathy D, Giordano S. Palbociclib in advanced male hormone positive breast cancer. Cancer Res 80(4 Suppl), 2020. e-Pub 2020.
32. Clifton KK, Raghavendra AS, Yi M, Litton J, Tripathy D, Karuturi M. Practice patterns and outcomes of post progression treatment after CDK 4/6 inhibitors [abstract]. Cancer Res 80(4 Suppl), 2020. e-Pub 2020.
33. Raghavendra AS, Kypriotakis G, Karam-Hage M, Jizzini M, Seoudy K, Cinciripini P, Ibrahim N. The impact of smoking cessation on breast cancer patients’ survival. 7th State of the Science Cancer Survivorship Research Symposium, 2019. e-Pub 2019.
34. Raghavendra AS, Barcenas C, Hwang H, Wang X, Eke C, Avirineni A, Abu-Sbeih H, Garg N, Lum P, Miller E. Clinical significance of elevated liver enzymes after exposure to endocrine therapy in early-stage breast cancer patients. 7th State of the Science Cancer Survivorship Research Symposium, 2019. e-Pub 2019.
35. Stauder MC, Tereffe W, Shaitelman SF, Smith BD, Yeboa DN, Reed VK, Delclos ME, Ibrahim N, Raghavendra AS, Karuturi MS, Keyomarsi K, Tripathy D, Woodward WA. Toxicity of radiation therapy given concomitantly with palbociclib for metastatic breast carcinoma. International Journal of Radiation Oncology• Biology• Physics 105(1 Suppl):E60, 2019. e-Pub 2019.
36. Trevino CR, Murthy RK, Raghavendra AS, Loghin M, Seligman C, Ferguson S, Kamiya-Matsuoka C, Harrison R, Sinicrope KD, Valero V, Tummala S, Hess K, Tripathy D, de Groot J, and O’Brien B. LPTO-08. INTRATHECAL TRASTUZUMAB PLUS/MINUS IT TOPOTECAN FOR PATIENTS WITH HER2+ BREAST CANCER AND LEPTOMENINGEAL METASTASIS. Neurooncol Adv 1(1):i7–i8, 2019. e-Pub 2019.
37. Kettner NM, Vijayaraghavan S, Durak MG, Bui T, Kohansal M, Ha MJ, Liu B, Rao X, Wang J, Yi M, Carey JPW, Chen X, Eckols TK, Raghavendra AS, Ibrahim NK, Karuturi MS, Watowich SS, Sahin A, Tweardy DJ, Hunt KK, Tripathy D, Keyomarsi K. Combined inhibition of STAT-3 & DNA repair in palbociclib resistant breast cancer. Clin Can Res 25(13):3996–4013, 2019. e-Pub 2019.
38. Jizzini M, Raghavendra AS, Ibrahim NK, Kypriotakis G, Cinciripini PM, Seoudy K, Karam-Hage MA. The impact of smoking cessation on breast cancer patients' survival. Clinical Oncology 37(15), 2019. e-Pub 2019.
39. Fujii T, Masuda H, Cheng YC, Yang F, Sahin AA, Naoi Y, Matsunaga Y, Raghavendra AS, Sinha AK, Fernandez JRE, James A, Yamagishi K, Matsushima T, Tripathy D, Tada S, Jackson RS, Noguchi S, Nakamura S, Acoba JD, Ueno NT. A novel 95-gene signature (Curebest 95GC Breast) that predicts recurrence-risk in patients with ER-positive, HER2-negative, node-negative, early-stage primary invasive breast cancer with an intermediate Oncotype DX Recurrence Score. J Clin Oncol 37(15 Suppl), 2019. e-Pub 2019.
40. Garber H, Raghavendra AS, Hess KR, Arun B, and Ibrahim NK. Brain metastasis in patients with hereditary BRCA-mutated invasive breast cancer. J Clin Oncol 37(15 Suppl):1074, 2019. e-Pub 2019.
41. Murthy RK, Raghavendra AS, Hess KR, Barcenas CH, Lim B, Moulder SL, Giordano SH, Mittendorf EA, Thompson A, Ueno NT, Valero V, Litton JK, Tripathy D, Chavez-Macgregor M. 3-year relapse-free survival of stage II-III HER2-neu positive breast cancer treated with pertuzumab and trastuzumab-containing neoadjuvant therapy compared to trastuzumab-containing therapy. Cancer Res 79(4 Supl), 2019. e-Pub 2019.
42. Caswell-Jin JL, McNamara K, Reiter JG, Sun R, Hu Z, Ma Z, Raghavendra A, and Chin SF. Clonal evolution and heterogeneity in breast tumors treated with neoadjuvant HER2-targeted therapy. Cancer Res(79):4 Suppl, 2019. e-Pub 2019.
43. Yam C, Raghavendra A, Hess KR, Adrada BE, Candelaria RP, Damodaran SD, Gilcrease MZ Helgason T, Hortobagyi GN, Huo L, Layman RM, Lim B, Litton JK, Mittendorf EA, Murthy RK, Piwnica-Worms H, Rauch GM, Santiago L, Symmans F, Thompson AM, Tripathy D, Ueno NT, Valero V, Barcenas CH, Moulder SL, Yang W. Impact of serial biopsies in triple-negative breast cancer patients receiving neoadjuvant systemic therapy. Cancer Res 79(4 Suppl), 2019. e-Pub 2019.
44. Mylander C, Rosman M, Gage M, Fujii T, Le Du F, A <, Sinha A, Fernandez J, James A, Ueno N, Tafra L, Jackson R. Getting the most out of the 21-gene recurrence score assay: Increasing actionable results with a combined pathologic-genomic model. Cancer Res 78(Suppl 4), 2018. e-Pub 2018.
45. Murthy RK, Raghavendra A, Hess K, Zhang H, Lim B, Barcenas CH, Chavez-MacGregor M, Mittendorf E, Litton J, Giordano S, Thompson A, Valero V, Tripathy D, Ueno N. Patterns of use and effectiveness of neoadjuvant pertuzumab-containing regimens in stage II-III HER2-neu positive breast cancer: A retrospective, single institutional experience [abstract]. Cancer Res 78(Suppl 4), 2018. e-Pub 2018.
46. Vijayaraghavan S, Karakas C, Doostan I, Chen X, Bui T, Yi M, Raghavendra AS, Zhao Y, Bashour SI, Ibrahim NK, Karuturi M, Wang J, Winkler JD, Amaravadi RK, Hunt KK, Tripathy D, Keyomarsi K. CDK4/6 and autophagy inhibitors synergize to induce senescence in cancers with an intact G1/S checkpoint. Cancer Research 77(13 Supplement), 2017. e-Pub 2017.
47. Murthy RK, Fujii T, Hess K, Raghavendra A, Lim B, Barcenas CH, Zhang H, Chavez-Mac Gregor M, Mittendorf E, Litton J, Giordano S, Thompson A, Valero V, Tripathy D, Ueno T. Effect of neoadjuvant pertuzumab-containing regimens on pathologic complete response rates in stage II-III HER2-neu positive breast cancer: A retrospective, single institutional experience. J Clin Oncol 25(Suppl 15):580, 2017. e-Pub 2017.
48. Wong Y, Raghavendra A, Hatzis C, Irizarry J, Vega T, Barcenas CH, Chavez-Mac Gregor M, Valero V, Tripathy D, Pusztai L, Murthy RK. Long-term survival of de novo stage IV human epidermal growth factor receptor 2 (HER2)-positive breast cancers treated with HER2 targeted therapy. J Clin Oncol 35(Suppl 5):1021, 2017. e-Pub 2017.
49. Raghavendra A, Sinha A, Janeiro V, Shen Y, Tripathy D, Barcenas CH. Determinants of weight gain during adjuvant endocrine therapy and association of such weight gain with recurrence in long-term breast cancer survivors. Fifth State of the Science Cancer Survivorship Research Symposium (MD Anderson Cancer Center), 2017. e-Pub 2017.
50. Mylander C, Jackson RS, Rosman M, Fujii T, Le Du F, Raghavendra A, Sinha A, Ueno NT, Tafra L. A model using grade and hormone receptor staining defines groups at low vs. high risk for distant metastasis: Comparison to the 21-gene recurrence score [abstract]. Cancer Res 77(Suppl 4), 2017. e-Pub 2017.
51. Báez-Vallecillo L, Singareeka Raghavendra A, Hess K, Moulder SL, Tripathy D, Valero V, Murthy RK. Lapatinib after pertuzumab and ado-trastuzumab emtansine in metastatic HER2-positive breast cancer. Cancer Res 77(Suppl 4), 2017. e-Pub 2017.
52. Murthy RK, Song J, Raghavendra AS, Li Y, Hsu L, Barcenas CH, Tripathy D, Berry D, Hortobagyi GN. Proposal for a new breast cancer staging classification: Incorporating clinical and biologic factors. Cancer Res(77):Suppl 4, 2017. e-Pub 2017.
53. Dzimitrowicz H, Berger M, Vargo C, Hood A, Abdelghany O, Raghavendra A, Tripathy D, Valero V, Hatzis C, Pusztai L, Murthy R. T-DM1 activity in metastatic HER2-positive breast cancers that received prior therapy with trastuzumab and pertuzumab. Clin Oncol 34(29):3511-7, 2016. e-Pub 2016.
54. Raghavendra A, Sinha AK, Hsu L, Patangan Jr M, Bevers TB, Le-Petross H, Tripathy D, Bedrosian I, Barcenas C. Association between tumor stage of first non-metastatic breast cancer and second contralateral breast cancer. J Clin Oncol 34(3), 2016. e-Pub 2016.
55. Barcenas CH, Sinha AK, Raghavendra A, Syed MP, Hsu L, Patangan M, Gregor MC, Shen Y, Giordano S, Ueno N, Valero V, Tripathy D. Outcomes after chemotherapy in early-stage breast cancer (EBC) patients who underwent a 21-gene expression assay (Oncotype-DX). J Clin Oncol 34(15):559, 2016. e-Pub 2016.
56. Barrak D, Tung L, Ayoub Z, Ring A, Raghavendra AS, Tripathy D, , Lang JE. Incidence rate and outcomes for palpable ductal carcinoma in situ in the contemporary era. Ann Surg Oncol 33:36-7, 2016. e-Pub 2016.
57. Raghavendra A, Sinha AK, Garg N, Hsu L, Patangan Jr M, Bevers T, Arun B, Le-Petross H, Tripathy D, Bedrosian I, Barcenas C. Association Between Mammographic Breast Density (BD) and the Development of a Second Contralateral Breast Cancer (CBC): A Nested Case-control Study. ANNALS OF SURGICAL ONCOLOGY 23:S25-S25, 2016. e-Pub 2016.
58. Sprunt J, Barrak D, Morocco E, Pan E, Wu G, Tung L, Wecsler J, Raghavendra A, Ragab O, Chung E, Tripathy D. A Matched Pair Cohort Study of the Effect of Neoadjuvant Chemotherapy in Stage I-III Breast Cancer. ANNALS OF SURGICAL ONCOLOGY 23:S48-S48, 2016. e-Pub 2016.
59. Raghavendra A, Sinha AK, Garg N, Hsu L, Patangan Jr M, Arun B, Bevers TB, Le-Petross H, Tripathy D, Bedrosian I, Barcenas C. Association between mammographic breast density of first breast cancer and the development of a second contralateral breast cancer. Fourth State of the Science Cancer Survivorship Research Symposium, 2016. e-Pub 2016.
60. Raghavendra A, Soones T, Lowenstein L, Tripathy D, Karuturi M. Optimizing care for elderly breast cancer (EBC) Patients: Insights from SeniorERA (Encouraging resilience in aging) assessments. SIOG.
61. Luo L, Yang P, Mastoraki S, Wang Y, Kettner NM, Raghavendra AS, Tripathy D, Damodaran S, Hunt KK, Li Z, Keyomarsi K. Single-cell RNA sequencing reveals metastatic site-specific biomarkers for predicting response to CDK4/6 inhibition in advanced HR+/HER2-breast cancer. AACR.
62. Luo L, Wang Y, Mastoraki S, Raghavendra AS, Navarro-Yepes J, Kettner NM, Kim S, Tripathy D, Hunt K, Keyomarsi K. TFF1 and TFF3 predict response to CDK4/6 inhibitors in breast cancer patients.
63. Garrido-Castro A, Zakon DB, Jin Q, Grimm M, Raghavendra AS, Hughes M, Cherian M, Vincuilla J, Parker T, Tarantino P, Mittendorf E, King T, Valero V, Tripathy D, Ramaswamy B, Tolaney S, Tayob N, Lin N, Stover D, Barcenas C. Clinical outcomes in early-stage TNBC according to HER2-low status.
64. Raghavendra AS, Kotecki N, Jennings K, Amato O, Tripathy D, Awada A, Ibrahim N. Nomogram for predicting brain metastasis in early-stage breast cancer patients.
65. Navarro-Yepes J, Kettner N, Rao X, Bui T, Bishop C, Wingate H, Raghavendra AS, Wang Y, Wang J, Sahin A, Meric-Bernstam F, Hunt K, Damodaran S, Tripathy D, Keyomarsi K. Abemaciclib is effective in palbociclib resistant estrogen receptor positive breast cancers. SABCS 2023.
66. Mouabbi J, Pasyar S, Bassett R, Raghavendra AS, Hassan A, Layman R, Tripathy D. MDA iLobular Prognostic Tool: A Novel Approach for Risk Stratification in Invasive Lobular Carcinoma.
67. Raghavendra AS, Wang Z, Bassett R, Tripathy D. Antibody-Drug Conjugates (ADCs) in Breast Cancer: Real World Analysis of Outcomes.
68. O'Brien B, Murthy RK, Berry D, Raghavendra A, Monroe M, Johnson J, Schwartz-Gomez J, Topletz-Erickson A, Lobbous M, Melisko M, Morikawa A, Ferguson S, Frederick de Groot J, Krop I, Vicente V, Rimaw M, Wolff A, Tripathy D, Lin N, Stringer-Reasor E. Tucatinib-trastuzumab-capecitabine for treatment of leptomeningeal metastasis in HER2+ breast cancer: TBCRC049 phase 2 study results.
69. Jennings K, Raghavendra A, Kotecki N, Amato O, Tripathy D, Awada A, Ibrahim N. EXTERNALLY VALIDATED PREDICTIVE NOMOGRAM FOR BRAIN METASTASIS IN EARLY-STAGE BREAST CANCER.
70. Raghavendra A, Kaler A, Hsu L, Kirklin G, Hui D, Tripathy D. The role of patient navigation (PN) in delivering goal-concordant care to advanced breast cancer (ABC) patients.

Letters to the Editor

1. Barcenas, CH, Song, J, Murthy, RK, Singareeka Raghavendra, A, Li, Y, Hsu, L, Carlson, RW, Tripathy, D, Hortobagyi, GN. Reply to A. Pfob and C. Sidey-Gibbons. JCO Clinical Cancer Informatics, 2022.